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Abstract
Background: Tumor cells use aerobic glycolysis to rapidly generate ATP and growth substrate which expenses a
large amount of glucose. However, how tumor cells take in enough glucose from the tumor microenvironment of
insufficient blood supply remains poorly understood. The cellular FLICE-like inhibitory protein (FLIP), a cell apoptosis
inhibiting molecule, is highly expressed in hepatocellular carcinoma (HCC) and is implicated in HCC development.
Methods: The effects of FLIPL (the long form of FLIP) on aerobic glycolysis and glucose uptake were assessed in
HCC cells and xenograft tumors. The correlations between FLIPL expression and sodium/glucose cotransporter 1
(SGLT1) expression in clinical HCC tissues were analyzed. The consequences of FLIPL-induced regulation of SGLT1
at the transcription and translation levels and the interaction between FLIPL and SGLT1 were examined. FLIPL-mediated
tolerance upon glucose limitation and its mechanism were detected.
Results: We report a novel role for FLIPL in promoting the aerobic glycolysis of HCC cells. FLIPL overexpression induced
a significant increase in cell aerobic glycolysis indexes including glucose uptake, glucose consumption, and
lactate production. FLIPL co-localized and interacted with SGLT1, a major active glucose transporter in HCC cells.
FLIPL increased the stability of SGLT1 protein by inhibiting its ubiquitination and degradation. The expression
level of FLIPL was positively correlated with the expression level of SGLT1 in 79 HCC tissues from surgical operation.
Furthermore, FLIPL increased cell tolerance ability and decreased cell apoptosis to low glucose by regulating SGLT1.
Conclusions: Our results indicate that FLIPL plays an essential role in HCC aerobic glycolysis and that SGLT1 is
required for FLIPL-modulated tumor proliferation under low glucose conditions. Targeting the actions of FLIPL in
cell glucose-dependent aerobic glycolysis may provide an attractive strategy for therapeutic intervention in HCC.
Keywords: Hepatocellular carcinoma, Cellular FLICE-like inhibitory protein, Sodium-glucose cotransporter 1,
Aerobic glycolysis, Glucose uptake
Background
Hepatocellular carcinoma (HCC) is a highly aggressive
malignant tumor worldwide. Due to the resistance of
HCC to conventional therapies, such as radiotherapy and
chemotherapy, hepatic resection remains the most effect-
ive method for treating HCC [1, 2]. However, many pa-
tients have already lost the opportunity for hepatic
resection by the time that HCC is diagnosed. Therefore,
continued efforts are needed to find new targets for HCC
treatment.
Tumor cells convert most glucose into lactate regardless
of whether oxygen supply is sufficient. This aerobic glyco-
lytic metabolism is known as the Warburg effect [3].
Tumor cells utilize aerobic glycolysis to rapidly generate
ATP and other substrates to meet the need of tumor
growth [4]. In view of the fact that aerobic glycolysis is
much less efficient than oxidative phosphorylation for
generating ATP [5], tumor cells need to increase glucose
absorption to meet the high requirement for glucose me-
tabolism [6]. Multiple oncogenes and tumor suppressor
genes participate in the glucose uptake and metabolism
processes, including PI3K, AKT, AMPK, p53, c-Myc, and
* Correspondence: liyann@fmmu.edu.cn; duxl0705@fmmu.edu.cn;
Dxlin0715@163.com
†Equal contributors
2Department of Biochemistry and Molecular Biology, The Fourth Military
Medical University, 169 Changle West Road, Xi’an, Shaanxi 710032, China
1Department of General Surgery, Tangdu Hospital, The Fourth Military
Medical University, 1 Xinsi Road, Xi’an 710032, Shaanxi, China
Full list of author information is available at the end of the article
© 2016 Lei et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Lei et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:79 
DOI 10.1186/s13046-016-0358-3
HIF-1α [7, 8]. These regulators increase glucose uptake by
enhancing the transcription and membrane translocation
of glucose transporters in tumor cells. There are two clas-
ses of glucose transporters in humans, the facilitated
transporters (GLUTs) and the active transporters (SGLTs).
Previous studies have revealed that ectopic expression of
glucose transporters in many tumors is beneficial to cell
proliferation and survival under low glucose condition [9].
It has been reported that there is abnormal GLUT1 ex-
pression in HCC [10]. Despite glucose transporters is sig-
nificant in tumor aerobic glycolysis, the key molecules and
precise mechanisms controlling the glucose transporters
are still largely unknown.
Cellular FLICE-like inhibitory protein (FLIP) is a po-
tential oncogene in HCC, which highly homologous to
caspase-8 containing two death effector domains [11].
The human FLIP gene is located on chromosome 2q33-
q34. Three splice variants of the FLIP protein have been
identified, a 55 kDa long form FLIP (FLIPL), a 27 kDa
short form FLIP (FLIPS) and a 25 kDa FLIP Raji (FLIPR)
[12]. These isoforms perform different cellular functions
[12], with FLIPL being the most well-studied isoform. El-
evated FLIPL is observed in many cancers, including
HCC, malignant melanoma, breast cancer, prostate can-
cer, bladder cancer, and non-Hodgkin lymphoma [13].
FLIPL has been shown to be a multifunctional protein
involved in death receptor-mediated apoptosis, the NF-
κB pathway [14, 15], necrosis [16], autophagy [17], in-
flammation [18], the ubiquitin-proteasome system [19],
and endoplasmic reticulum morphology [20]. Recently,
FLIPL was shown to be up-regulated following the dis-
ruption of glycolysis with 2-deoxy-D-glucose (2-DG)
[21]. However, whether and how FLIPL participates in
glucose metabolism in cancer cells is unclear.
In the current study, we first demonstrated the function
of FLIPL in facilitating HCC cells’ aerobic glycolysis by
modulating SGLT1-mediated glucose uptake. We found
SGLT1 is required for FLIPL induced cell aerobic glycoly-
sis and survival to low glucose conditions. We also ex-
tended our findings to clinical HCC patients. In 79 HCC
cases, FLIPL expression level was positively correlated with
SGLT1 expression level. Therefore, our results suggest
that FLIPL is a potential therapeutic target for HCC [22].
Methods
Cells and reagents
HepG2, MHCC97-H, Huh-7, SMMC-7721, BEL-7704
HCC, and HEK293 cell lines were obtained from the De-
partment of Biochemistry and Molecular Biology (The
Fourth Military Medical University) and cultured in a hu-
midified incubator under 5 % CO2 in Dulbecco’s modified
Eagle’s medium (DMEM) (Life Technologies, Carlsbad, CA,
USA) supplemented with 10 % fetal bovine serum (FBS),
2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml
streptomycin at 37 °C. The proteasome inhibitor, MG132,
was from Sigma-Aldrich (Shanghai, China). Mouse anti-
GLUT1, rabbit anti-SGLT1 and mouse anti-FLIP antibodies
were obtained from Abcam (New Territories, HK). Rabbit
anti-FLIP and mouse anti-HA-Tag antibodies were from
Cell Signaling Technology (Danvers, MA). 2-NBDG (2-[N-
(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-2-deoxy -D-glu-
cose) was purchased from Cayman Chemical Company
(Michigan, US).
Cell transfections
FLIPL expression plasmid (Flag-FLIPL), FLIPS expression
plasmid (Flag-FLIPS), SGLT1 expression plasmid (Myc-
SGLT1), HA-ubiquitin expression plasmid, shRNA target-
ing FLIPL, and shRNA targeting SGLT1 were constructed
by Jikai biotechnology (Shanghai, China). Cells (1 × 106)
were seeded into six-well plates and transfected using Li-
pofectamine 2000 (Invitrogen Life Technologies, Carlsbad,
USA) according to the manufacturer’s instructions. The
target sequences of shRNA of FLIPL and SGLT1 are 5’ C
AGAATAGACCTGAAGACA3’ and 5’ CTTCCGCATC
CAGGT CAAT3’, respectively.
Real-time PCR
RNA was reverse transcribed with the PrimeScript™ 1st
Strand cDNA Synthesis Kit (Takara, Dalian, China) ac-
cording to the manufacturer's instructions. Real-time PCR
was performed using SYBR Premix Ex Taq™ II (Takara,
Dalian, China). The relative gene expression was calcu-
lated using the 2−ΔΔCt method, in which Ct represented
the threshold cycle. β-actin RNA was used as the refer-
ence. The primers were used as following. FLIPL: Forward
5’GGCTCCCCCTGCATCAC3’, Reverse 5’ TTTGGCTT
CCTGCTAGATAAGG3’; SGLT1: Forward 5’ATGGA
CAGTAGCACCTTGAGCC3’; Reverse 5’TAGCCCCAG
AGAAGATGTCTGC3’; GLUT1: Forward 5’AAGTCTCC
TTTACCCACATCC 3’; Reverse 5’ GAGTGTCCGTGTC
TTCTTGAGT 3’.
Immunoblot analysis
Cells were harvested and lysed with RIPA buffer (0.15 M
NaCl, 1 % NP40, 0.01 M deoxycholate, 0.1 % SDS, 0.05 M
Tris-HCl pH 8.0, 1 mM sodium orthovanadate, 1 mM phe-
nylmethylsulfonyl fluoride, 10 mg/ml aprotinin, 10 mg/ml
pepstatin and 10 mg/ml leupeptin). Protein concentra-
tions were determined using the BCA Protein Assay kit
(Beyotime, China). The total protein was electropho-
resed on 8 or 12 % SDS-PAGE gels and transferred to
polyvinylidene fluoride membranes. Membranes were
blocked with 5 % nonfat dry milk or BSA in TBST buf-
fer (20 mM Tris-HCl pH 7.4, 8 g/L NaCl and 0.1 %
Tween 20) for 1 h at room temperature, and then incu-
bated with the indicated primary antibody in TBST buf-
fer containing 2 % BSA at 4 °C overnight. The
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membrane was then probed with the appropriate horse-
radish peroxidase-conjugated secondary antibody at room
temperature for 1 h, and the proteins were detected with a
chemiluminescence imaging analysis system.
Glucose uptake assay in vitro
Cells were plated at 1×106/well in 6-well plates and cul-
tured for 24 h. After the specified treatments, cells were
refreshed with serum-starved (0.1 % FBS) and glucose-
free DMEM. 16 h later, cells were grown in the presence
of 50 mM 2-NBDG for 30 or 60 min, respectively, and
glucose uptake was quantified using FACS analysis.
Tumorigenesis and glucose uptake assay in vivo
5×106 of HepG2 cells were injected into the hind legs of
athymic male nude mice (8 weeks, seven mice per
group). The tumor size was measured weekly with a cali-
per, and the tumor volume was determined with the
standard formula: 0.5×length×width2. The tumor growth
curve was then derived from these data. 18F-FDG was
injected into the mice via a tail vein and PET/CT images
were collected on a nanoScan PET/CT system (Mediso,
Budapest, Hungary).
Lactate production assay
1×105 cells were plated in 6-well plates and cultured
overnight. Culture medium was removed from cells and
the lactate concentration was determined using the Lac-
tate Kit (Nangjing Jiancheng Bioengineering, Nanjing,
China) according to manufacturer’s protocol. Cells were
then harvested, stained with trypan blue, and the num-
ber of viable cells was counted using a hemocytometer.
The rate of lactate production was determined (lactate
production rate=lactate concentration/cells/time) and
normalized to the rate detected in the control group.
Glycolysis assay
Extracellular acidification rate (ECAR) was conducted
using a Seahorse XF24 Analyzer. 20,000 cells were seeded
into Seahorse 24-well microplates and cultured at 37 °C
with 5 % CO2 for 24 h. Culture medium was replaced with
700 μl of assay medium, composed of DMEM without
FBS and sodium bicarbonate, and cells were then incu-
bated at 37 °C without CO2 for 1 h. To measure the glyco-
lytic capacity of the cells, additions were injected to the
wells at final concentrations of 11 mM glucose, 1 μM oli-
gomycin, and 20 mM 2-DG.
Immunofluorescence assay
Cells were fixed in a freshly prepared 4 % paraformalde-
hyde, rinsed with 0.1 % PBS and permeabilized with Triton
X-100. Cells were then incubated with horse serum in PBS
to block nonspecific binding. After being washed with PBS,
cells were incubated overnight at 4 °C with mouse anti-
FLIP antibody (1:200), rabbit anti-SGLT1 antibody (1:200).
Subsequently, fluorescein isothiocyanate-conjugated anti-
mouse antibody (diluted 1:400; Sigma-Aldrich) or cyanine
3-conjugated anti-rabbit antibody (diluted 1:400; Sigma-
Aldrich) were incubated with the cells at room temperature
for 2 h. The isotype mouse and rabbit IgG were used as
negative controls. Fluorescence detection was performed
using a laser confocal microscope (Nikon, US) after cell nu-
cleus counterstaining with 4’, 6-diamidino-2-phenylindole.
Immunoprecipitation
Cells were incubated with 1 ml of lysis buffer containing
(50 mM HEPES, pH 7.4; 150 mM NaCl; 0.1 % Triton X-
100; 1.5 mM MgCl2; 1 mM EDTA; and 1 mM phenyl-
methylsulfonyl fluoride), as well as protease inhibitors
for 30 min at 4 °C. The insoluble fraction was eliminated
through centrifugation at 12,000 rpm for 30 min at 4 °C.
The lysates were incubated with the antibody after cen-
trifugation and protein A/G-conjugated sepharose (Santa
Cruz Bio Technology, USA) at 4 °C overnight. 20 μl of
protein was saved to quantify the total amount of pro-
tein loaded. Beads were washed four times with lysis
buffer. Proteins were eluted in SDS-PAGE sample buffer
and separated by SDS-PAGE for immunoblot analysis.
Cell proliferation assay
Cells were seeded into 96-well cell culture plates. Each
well contained 1×103 cells in 100 μl culture media. After
the specified treatments, the medium in each well was
replaced with 100 μl fresh medium with 10 % CCK8
(Dojindo, Japan), and the cells incubated at 37 °C for
additional 2 h. The absorbance was measured at 450 nm
wavelength.
Cell apoptosis assay
Cells were cultured in MEM containing low glucose
(0.75 mM) or high glucose (25 mM) for 48 h after cell
transfection. For Annexin staining, cells were trypsinized
and resuspended in 1 ml Annexin-binding buffer (BD Bio-
sciences, US) to which was added 5 μl Annexin V-FITC
(BD Biosciences, US). After incubation in the dark at room
temperature for 15 min, 50 μl PI (Sigma, US) was added to
discriminate dead cells and the samples were analyzed on a
FACS Caliber flow cytometer.
Tissue samples and study cohort and immunohistochemistry
(IHC)
All patients from whom we obtained the 79 pairs of
HCC and adjacent normal liver tissue specimens pro-
vided their full consent to participate in the study at the
Xijing Hospital of the Fourth Military Medical Univer-
sity (Xi’an, China). IHC was performed using the avidin-
biotin-peroxidase complex method. All sections were
deparaffinized in xylenes and dehydrated through a
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gradient concentration of alcohol before endogenous
peroxidase activity was blocked using 0.5 % H2O2 in
methanol for 10 min. After nonspecific binding was
blocked, the slides were incubated with FLIPL antibody
(1:200) or SGLT1 antibody (1:200) in phosphate-buffered
saline (PBS) at 4 °C overnight in a humidified container.
Biotinylated goat anti-rabbit immunoglobulin G (IgG)
(1:400; Sigma-Aldrich) was incubated with the sections
for 1 h at room temperature and detected using a
streptavidin-peroxidase complex. The brown color indi-
cative of peroxidase activity was developed by incubation
with 0.1 % 3, 3-diaminobenzidine in PBS with 0.05 %
H2O2 for 5 min at room temperature. An immunoreac-
tivity score system was provided on the basis of the pro-
portion and intensity of positively stained cancer cells.
The extensional standard used was as follows: (1) the
number of cells with positive staining (0–5 %: 0; 6–25 %:
1; 26–50 %: 2; 51–75 %: 3; and>75 %: 4) and (2) the
staining intensity (colorless: 0; pallide-flavens: 1; yellow:
2; brown: 3). We multiplied the numbers scored (1) and
(2) from the extensional standard, and the staining grade
was stratified as absent (0 score), weak (1–4 score),
moderate (5–8 score) or strong (9–12 score). Two pa-
thologists blinded to the clinicopathologic information
and outcome of the patients scored the multiple tissue
arrays. Tumors with moderate or strong immunostain-
ing intensity were classified as staining positive (+),
whereas tumors with absent were classified as staining
negative (−).
Statistical analysis
Data are reported as the mean ± S.D. or S.E.M. analyses
were performed using GraphPad Prism software. The sig-
nificance of differences was determined by one-way ana-
lysis of variance followed by Scheffe’s post hoc test,
independent samples t-test or Student’s t-test. Associations
between protein expression and categorical variables were
analyzed using the χ2 test or Fisher’s exact test as appropri-
ate. P < 0.05 was considered statistically significant.
Results
FLIPL facilitates aerobic glycolysis by promoting glucose
uptake
To investigate whether FLIP could affect aerobic glycoly-
sis in HCC, FLIPL and FLIPS, the two main isoforms of
FLIP, were overexpressed in HepG2 cells (Fig. 1a, b).
Overexpressed FLIPL significantly increased aerobic
glycolytic capacity in response to glucose stimulation
compared with the control group, but overexpressed
FLIPS had no effect on glycolysis (Fig. 1c, d). We also
found that FLIPL, but not FLIPS, induced lactate produc-
tion (Fig. 1e), which was consistent with the ECAR re-
sults. These findings suggest that FLIPL is involved in
aerobic glycolysis in HCC.
Glucose uptake is a key step in aerobic glycolysis,
which is critical for cancer cell survival. Most cancer
cells generate high levels of ATP through increasing the
glucose uptake [23]. Therefore, we examined the effect
of FLIP on glucose uptake. Ectopic expression of FLIPL
significantly induced glucose uptake in HepG2 cells, but
glucose uptake was not altered in cells overexpressing
FLIPS (Fig. 1f ). Moreover, to evaluate the influence of
FLIPL on glucose uptake and HCC progression in vivo,
nude mice bearing FLIPL down-regulated HepG2 cells
(Fig. 1g, h) were imaged by 18F-FDG PET/CT scanning.
The scan images demonstrated that 18F-FDG accumula-
tion was notably decreased with the deletion of FLIPL
(Fig. 1i, j). We also analyzed the effect of FLIPL on HCC
development by continuously measuring the size of tu-
mors in the xenograft mouse model. As shown in Fig. 1k,
the growth of transplanted tumors with FLIPL silenced
was significantly slower, compared with the control
group. These results indicated that FLIPL promotes
tumor cell survival and aerobic glycolysis by increasing
glucose uptake both in vivo and in vitro.
FLIPL expression positively correlated with SGLT1
expression in hepatic carcinoma
Glucose is transported into cells by two families of trans-
porters, the facilitative-type glucose transporters and the
active-type glucose transporters [24]. GLUT1 and SGLT1,
two well-studied glucose transporters in the respective
families, are highly expressed in several cancers and par-
ticipate in cellular glucose uptake. To determinate the
mechanisms by which FLIPL promotes the aerobic gly-
colysis and survival of HCC cells, we measured the
GLUT1 and SGLT1 mRNA and protein levels after
shRNA-mediated depletion of FLIPL expression in HepG2
cells. Although the mRNA level of SGLT1 did not change,
its protein expression was notably decreased following
FLIPL loss. However, neither mRNA nor protein levels of
GLUT1 altered with the down-regulation of FLIPL (Fig. 2a,
b). These findings suggested that SGLT1, but not GLUT1,
is involved in FLIPL-mediated HCC glucose uptake.
Dysregulated expression of SGLT1 has been identified
in various human cancers. However, the expression status
of SGLT1 in HCC has not been investigated. To assess
SGLT1 protein expression levels and its potential associ-
ation with FLIPL in HCC, we compared 79 pairs of HCC
and adjacent normal tissue samples using immunohisto-
chemistry (IHC). The results showed that SGLT1 and
FLIPL were highly expressed in liver cancer tissue com-
pared with adjacent normal liver tissue (Fig. 2c). In normal
versus liver cancer tissue, FLIPL levels were 0.41 versus
2.97 (Fig. 2d), and SGLT1 were 0.28 versus 2.47 (Fig. 2e).
Moreover, in these 79 pairs of HCC and adjacent normal
tissue samples, SGLT1 and FLIPL expression were corre-
lated with tumor stage (Tables 1 and 2) in liver cancer
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tissues, but the correlation between the expression and
sex or age was not statistically significant in both liver can-
cer tissues and their adjacent normal specimens (Tables 1
and 2, Additional file 1: Table S1 and Table S2).
Because knocking down FLIPL expression led to the sup-
pression of SGLT1 protein levels, we speculated whether
there is a correlation between the protein levels of FLIPL
and SGLT1. We analyzed the correlation between FLIPL
and SGLT1 expression using spearman analysis. The ex-
pression of FLIPL was demonstrated to positively correlate
with SGLT1 expression (Fig. 2f), suggesting that FLIPL is
involved in the post-transcriptional regulation of SGLT1.
Fig. 1 FLIPL promotes aerobic glycolysis by up-regulating glucose uptake. a and b HepG2 cells were transfected with FLIPL or FLIPs overexpression
vectors. Expression was detected 48 h after transfection in protein and mRNA levels. Data are the mean ± S.E.M. from three independent experiments.
**p < 0.01 versus the control group. Cell ECAR in c and d was measured by the glycolysis stress test in HepG2 cells with FLIPL or FLIPS overexpression.
Data represent the mean ± S.E.M. from three independent experiments, each performed in quadruplicate. *p < 0.05 versus the control group. e Lactate
production was measured in HepG2 cells with FLIPL or FLIPS overexpression. Data represent the mean ± S.E.M. from three independent experiments,
each performed in quadruplicate. *p < 0.05 versus the control group. f Glucose uptake was measured in HepG2 cells with FLIPL or FLIPS overexpression.
Cells were grown in the presence of the fluorescent analog 2-NBDG for various time points, and glucose uptake was quantified using FACS analysis.
Data represent the mean ± S.E.M. Similar results were obtained from three independent experiments. **p < 0.01 versus the control group. g and h
HepG2 cells were transfected with shFLIPL vector. Expression was detected 48 h after transfection in protein and mRNA levels. Data are the mean ±
S.E.M. from three independent experiments. **p < 0.01 versus the control group. i Representative PET/CT images in nude mice bearing liver tumors
with control or shFLIPL plasmid treatment. Yellow dotted lines indicate area of the liver tumors. j Glucose uptake in HCC was normalized with muscle
or liver tissues in each mouse (n=8). Data are presented as the mean ± S.D. *p < 0.05, **p < 0.01 versus control. k Tumor development in nude mice
bearing with FLIPL-silent HepG2 cells (n=8). Data are presented as the mean ± S.D. *p < 0.05 versus control
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Fig. 2 FLIPL expression positively correlated with SGLT1 expression in HCC. GLUT1 and SGLT1 expression were determined by real-time PCR (a) and
immunoblot analysis (b) in HepG2 cells with FLIPL knockdown treatment. Left panel: Immunoblotting. Right panel: Densitometric quantification of the
data in b, normalized to β-tubulin. Data are the mean ± S.E.M. from three independent experiments. *p < 0.05, **p < 0.01 versus the control group.
c IHC staining of FLIPL and SGLT1 in adjacent normal and liver cancer samples from patients at different stages. Case 1 is from a stage II patient, and Case
2 is from a stage I patient. Bar = 200 μm. (d) and (e) Quantification of the expression levels of FLIPL and SGLT1 in human HCC samples. **p < 0.01 versus
adjacent normal tissues. f Correlation between FLIPL and SGLT1 expression with linear regression and Pearson’s correlation significance (p < 0.01)
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FLIPL interacts with SGLT1
Given that FLIPL could regulate the protein level of
SGLT1, but not the SGLT1 transcript, we investigated
whether the FLIPL protein interacts with the SGLT1
protein. To address this question, we examined the
subcellular distribution of FLIPL and SGLT1 in HepG2
cells using immunofluorescence. Both FLIPL and
SGLT1 were predominantly localized in the cytoplasm
and there was a strong co-localization of the two pro-
teins (Fig. 3a). The co-localization of FLIPL and SGLT1
prompted us to further analyze whether FLIPL could
bind with SGLT1. Co-immunoprecipitation was per-
formed using lysates prepared from HepG2 cells, and
showed that endogenous FLIPL interacted with en-
dogenous SGLT1, and vice versa (Fig. 3b).
FLIPL inhibits the ubiquitination and degradation of
SGLT1
FLIPL has been shown to up-regulate the levels of some
proteins by inhibiting the ubiquitin-proteasome degrad-
ation pathway [19]. We hypothesized that FLIPL stabilizes
SGLT1 protein by regulating its degradation. First we de-
termined the protein degradation pathway of SGLT1. As
shown in Fig. 3c, FLIPL increased the SGLT1 protein level
and MG132, a proteasome inhibitor, induced further accu-
mulation of SGLT1 protein, indicating that the degrad-
ation of SGLT1 protein occurs via a proteasome associated
pathway. In addition, we examined the effect of FLIPL on
SGLT1 ubiquitination in HEK293 cells and HepG2 cells.
In HEK293 cells, exogenous FLIPL inhibited the ubiquiti-
nation of exogenous SGLT1 and increased the total levels
of SGLT1 protein (Fig. 3d). Endogenous SGLT1 ubiquiti-
nation was also examined in HepG2 cells and, consistent
with the results with the exogenous proteins in HEK293
cells, we found that down-regulation of the expression of
FLIPL led to increased SGLT1 ubiquitination and acceler-
ated SGLT1 degradation (Fig. 3e). Collectively, these re-
sults suggested that FLIPL interacts with SGLT1 in the
cytoplasm and increases the stability of SGLT1 protein by
inhibiting its ubiquitination and proteasome-mediated
degradation. This promotes the membrane translocation
and function of SGLT1.
FLIPL promotes the tolerance of HCC cells to low glucose
High level of glycolysis could not only rapidly provide
ATP for cancer cell proliferation but also allow cancer
cells to adapt low glucose condition [9]. We investi-
gated whether and how FLIPL regulates the tolerance
for low glucose of HCC cells. We first assessed the abil-
ity of several HCC cell lines to tolerate low glucose.
The apoptosis levels of HepG2, MHCC97-H, Huh-7,
SMMC-7721 and BEL-7704 were detected under high
glucose condition (25 mM) and low glucose condition
(0.75 mM). Of these cell lines, HepG2, MHCC97-H,
and Huh-7 cells exhibited higher tolerance of the low
glucose condition (Fig. 4a). We next examined the
FLIPL and SGLT1 expressions in these cell lines. FLIPL
and SGLT1 protein levels were higher in two of the cell
lines tolerant to low glucose, HepG2 and Huh-7 cells
(Fig. 4b), so we used the HepG2 cells to perform the
following experiments.
To determine whether FLIPL and SGLT1 affect the
susceptibility of HCC cells to low glucose conditions,
FLIPL and SGLT1 were separately down-regulated in
HepG2 cells (Figs. 1g, h, and 4c, d). Examination of cell
apoptosis, as shown in Fig. 4e, f, showed that apoptosis
rates were significantly increased in FLIPL-silenced or
SGLT1-silenced HepG2 cells. In addition, we found that
the loss of FLIPL inhibited glucose uptake in HepG2
cells (Fig. 4g), which is consistent with the results of
Table 1 Statistical results of FLIPL expression in 79 liver cancer
specimens
N - +to+++ P-value
Total 79 24 55
Sex 0.605*
Male 66 20 46
Female 13 4 9
Age at diagnosis, years 0.437**
<60 61 18 35
≥60 18 6 20
TNM stage 0.015**
I 22 12 10
II 40 11 29
III 17 1 16
Abbreviation: TNM tumor node metastasis. *P-value when expression levels
were compared using Fisher’ exact test; **P-value when expression levels were
compared using the Kruskal-Wallis test
Table 2 Statistical results of SGLT1 expression 79 liver cancer
specimens
N - +to+++ P-value
Total 79 23 56
Sex 0.490*
Male 66 21 45
Female 13 2 9
Age at diagnosis, years 0.769*
<60 61 17 44
≥60 18 6 12
TNM stage 0.046**
I 22 9 13
II 40 13 27
III 17 1 16
Abbreviation: TNM tumor node metastasis. *P-value when expression levels
were compared using Fisher’ exact test; **P-value when expression levels were
compared using the Kruskal-Wallis test
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FLIPL overexpression in Fig. 1f. We next rescued the
SGLT1 expression in FLIPL-deficient HepG2 cells
(Fig. 4h, i), and the reduced glucose uptake was substan-
tially recovered (Fig. 4g). The increased apoptosis rate
was also attenuated with the restoration of SGLT1
expression in FLIPL-deficient HepG2 cells (Fig. 4j). In
addition, we examined the survival of HepG2 cells in a
low glucose environment. FLIPL-deficient HepG2 cells
exhibited a decreased cell proliferation rate, and rescued
SGLT1 expression significantly recovered cell survival
Fig. 3 FLIPL inhibits the ubiquitination and degradation of SGLT1 by interacting with SGLT1. a The localization of FLIPL and SGLT1 were determined in
HepG2 cells by laser confocal scanning microscopy. Green fluorescence indicated FLIPL expression, red fluorescence indicated SGLT1 expression, and
blue fluorescence indicated nuclear staining with DAPI. Bar = 20 μm. b HepG2 cells were harvested for co-immunoprecipitation assays followed by
immunoblot (IB) analysis. Immunoprecipitation (IP) assays were performed with whole-cell lysates (WCE) pretreated with A/G–conjugated
Sepharose beads. WCE were probed for input. The antibodies used for IP and IB are as indicated. c SGLT1 expression was determined in
HepG2 cells with FLIPL overexpression for 48 h and/or 5 μM MG132 for another 4 h. d HEK293 cells were transfected with hemagglutinin
(HA)-ubiquitin plasmid, Flag-FLIPL plasmid, and Myc-SGLT1 plasmid for 48 h. Subsequently, the cell lysates were collected and analyzed by
IP and IB. e HepG2 cells were transfected with HA-ubiquitin and shFLIPL plasmids for 48 h, and cell lysates were collected and analyzed
by IP and IB
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under low glucose treatment (Fig. 4k). These results
demonstrated that FLIPL promotes glucose uptake and
the survival of HCC cells under low glucose conditions
through regulation of SGLT1.
Discussion
In the present study, we determined a previous un-
known role for FLIPL in HCC cells aerobic glycolysis.
We have made three novel observations here. First, we
Fig. 4 FLIPL promotes low glucose tolerance in HCC cells. a FACS analysis was performed to determine the apoptosis of HepG2, MHCC97-H,
Huh-7, SMMC-7721 and BEL-7704 cells under low glucose (0.75 mM) or normal glucose (25 mM) treatment. b Immunoblot was used to detect
the FLIPL and SGLT1 expression in MHCC97-H, HepG2, Huh-7, BEL-7704, and SMMC-7721 cell lines. c, d HepG2 cells were transfected with shSGLT1
vector. Expression was detected 48 h after transfection at protein and mRNA levels. **p < 0.01 versus control. e The apoptosis was measured in
HepG2 cell with FLIPL knockdown treatment. Cells were cultured in low glucose (0.75 mM) or normal glucose (25 mM) and the levels of apoptosis
were determined by FACS analysis. f Apoptosis was measured in HepG2 cell with SGLT1 knockdown. Cells were cultured in low glucose (0.75 mM) or
normal glucose (25 mM), apoptosis was determined by FACS analysis. g Glucose uptake was measured in HepG2 cell with FLIPL knockdown or FLIPL
knockdown plus SGLT1 overexpression treatment. h, i FLIPL-deficient HepG2 cells were transfected with the SGLT1 overexpression vector. Expression
was detected 48 h after transfection at protein and mRNA levels. **p < 0.01 versus control. j Apoptosis was measured in HepG2 cell with FLIPL
knockdown, SGLT1 knockdown, and FLIPL knockdown plus SGLT1 overexpression treatment. k Cell proliferation was measured by CCK8 assay
in HepG2 cells with FLIPL knockdown, SGLT1 knockdown, and FLIPL knockdown plus SGLT1 overexpression treatment. (a, e, and f) Data represent the
mean ± S.E.M. from three independent experiments, each performed in quadruplicate. **p < 0.01 versus 25 mM glucose group. (g, i, j, and k) Data
represent the mean ± S.E.M. from three independent experiments, each performed in quadruplicate. *p < 0.05, **p < 0.01 versus control group;
#p < 0.05 versus shFLIPL group
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demonstrated that FLIPL interacted with SGLT1 to in-
hibit the ubiquitination of SGLT1, thereby promoting
glucose uptake and glycolysis in HCC cells. Second, we
found that FLIPL was highly expressed in HCC tissue
compared with adjacent normal tissue and that FLIPL
expression positively correlated with SGLT1 expres-
sion. Third, FLIPL increased tumor cell tolerance to
glucose limitation through the regulation of SGLT1
protein stability.
Glucose, as the main energy source of cells, is vital to
tumor cell proliferation. Aerobic glycolysis is a hallmark
in various tumors [25, 26]. Glucose uptake is the first
step in glycolysis. HCC enhanced glucose uptake to meet
the metabolic requirement of cells [27]. A previous study
has shown that a glucose transporter can be a novel and
attractive therapeutic target for HCC [28]. In the current
study, we found that SGLT1 was highly expressed in
HCC. Our findings support the notion that SGLT1 can
be a promising intervention target for HCC.
Multiple molecules are involved in the regulation of
tumor glucose metabolism. Investigating the factors that
control cancer cell aerobic glycolysis could not only ad-
vance the knowledge of the regulation of glucose metabol-
ism in cancer cells but also provide new approaches for
cancer therapy. Many factors have been shown to regulate
or affect aerobic glycolysis, oxidative phosphorylation,
pentose phosphate pathway, and glutamine metabolism.
The well-studied PI3K/AKT pathway [29] stimulates gly-
colysis by increasing glucose transporter expression and
membrane translocation and by phosphorylating the key
enzymes of glycolysis [30]. Hypoxia-inducible factor-1a
(HIF-1a) increases the glycolytic capacity by promoting
the transcription of genes encoding glucose transporters
and key enzyme of glycolysis [31]. FLIPL is aberrantly
expressed in HCC, and plays an important role in tumor
progression [11]. There is evidence showing that FLIPL
up-regulates AKT [32] and HIF-1 [19] expression. Consid-
ering that AKT/HIF-1 regulate glucose transporter ex-
pression, we cannot rule out that FLIPL might regulate
glycolysis through the HIF-1 or AKT signaling pathways.
Further studies are needed to explore this possibility.
As tumor cells proliferate, they consume large amounts
of nutrients, particularly glucose. However, the glucose
concentration of cancer tissues is frequently 3-6-fold lower
than normal tissue [33]. Therefore, tumor cells must have
the capacity to adapt to low levels of nutrients [8]. Aerobic
glycolysis is less efficient than oxidative phosphorylation
for generating ATP. However, this less efficient ATP gener-
ation is beneficial to cell proliferation [34]. Different tumor
cells exhibit diverse responses to glucose limitation, and
the glucose utilization and mitochondrial function deter-
mine the sensitivity to glucose limitation. Increased glu-
cose uptake promotes glycolysis, thereby increasing the
capacity to utilize glucose. GLUTs transport glucose into
cells depending on the glucose concentration gradient
across the cell membrane. In contrast, SGLTs do not rely
on the glucose concentration [35]. In prostate cancer,
SGLT1 enhanced the survival of tumor cells in low glucose
conditions by increasing the intracellular glucose level
[36]. We found that SGLT1 also promotes the survival of
HCC cells exposed to low glucose levels. Our findings in-
dicate that SGLT1 plays an important role in the adapta-
tion of HCC cells to glucose limitation.
The pathology of HCC is complicated due to the in-
volvement of multiple and distinct signaling pathways in
the initiation and development of HCC. This study re-
vealed that FLIPL not only promotes cell survival by
modulating cell apoptosis, autophagy, and necrosis [37]
but also affects glucose metabolism through the regula-
tion of SGLT1 in HCC. Our findings suggest that FLIPL
could be a potential intervention target for HCC therapy
in the future.
Conclusions
In the current study, we provided evidence strongly sug-
gesting that FLIPL, an apoptosis suppressor, is positively
correlated with SGLT1 expression in HCC. This correl-
ation is associated with FLIPL-induced glucose uptake
and glucose-dependent aerobic glycolysis. We have fur-
ther demonstrated that FLIPL plays a significant role in
the tolerance ability of HCC to low glucose, during
which FLIPL interacts with and protects SGLT1 from
proteasomal degradation. Although the contribution of
FLIPL to tumor onset and progression is complicated,
our findings first identified that FLIPL is involved in
HCC energy metabolism and is a promising therapeutic
target for future intervention for HCC.
Additional files
Additional file 1: Table S1. Statistical results for FLIPL expression in the
adjacent normal specimens of 79 HCC. Table S2. Statistical results of
SGLT1 expression in the adjacent normal specimens of 79 HCC.
(DOCX 17 kb)
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
All authors participated in the conception and design of this study. SXL, JDY,
and CC performed most of the experiments. JCS and LY analyzed the data.
HLT, TY, and AC provided formalin-fixed, paraffin-embedded, archived patient
materials and conducted pathologic reviews and clinical data evaluations.
HDZ reviewed the data. XLD and YL initiated the project and wrote the
paper. All authors read and approved the final manuscript.
Acknowledgements
This work was supported by the grants from National Natural Science
Foundation of China (81172287, 81372859, and 81471110), China
Postdoctoral Science Foundation funded project (2015 T81094 and
2014 M562599), Youth Science and Technology New Star Project of Shaanxi
Province (2015KJXX-49), and Science and Technology Project of Liaoning
Province (2015020412).
Lei et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:79 Page 10 of 11
Author details
1Department of General Surgery, Tangdu Hospital, The Fourth Military
Medical University, 1 Xinsi Road, Xi’an 710032, Shaanxi, China. 2Department
of Biochemistry and Molecular Biology, The Fourth Military Medical
University, 169 Changle West Road, Xi’an, Shaanxi 710032, China.
3Department of General Surgery, 210 Hospital of Chinese People’s Liberation
Army, Dalian 116021, China.
Received: 28 March 2016 Accepted: 6 May 2016
References
1. Roayaie S, Jibara G, Tabrizian P, Park JW, Yang J, Yan L, Schwartz M, Han G,
Izzo F, Chen M, et al. The role of hepatic resection in the treatment of
hepatocellular cancer. Hepatology. 2015;62:440–51.
2. Hayashi H, Beppu T, Okabe H, Kuroki H, Nakagawa S, Imai K, Nitta H,
Chikamoto A, Ishiko T, Baba H. Functional assessment versus conventional
volumetric assessment in the prediction of operative outcomes after major
hepatectomy. Surgery. 2015;157:20–6.
3. Warburg O, Wind F, Negelein E. The metabolism of tumors in the Body.
J Gen Physiol. 1927;8:519–30.
4. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg
effect: the metabolic requirements of cell proliferation. Science. 2009;324:
1029–33.
5. Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer's Achilles' heel.
Cancer Cell. 2008;13:472–82.
6. Gillies RJ, Robey I, Gatenby RA. Causes and consequences of increased
glucose metabolism of cancers. J Nucl Med. 2008;49 Suppl 2:24S–42S.
7. Shaw RJ. Glucose metabolism and cancer. Curr Opin Cell Biol. 2006;18:598–608.
8. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev
Cancer. 2011;11:85–95.
9. Birsoy K, Possemato R, Lorbeer FK, Bayraktar EC, Thiru P, Yucel B, Wang T,
Chen WW, Clish CB, Sabatini DM. Metabolic determinants of cancer cell
sensitivity to glucose limitation and biguanides. Nature. 2014;508:108–12.
10. Amann T, Kirovski G, Bosserhoff AK, Hellerbrand C. Analysis of a promoter
polymorphism of the GLUT1 gene in patients with hepatocellular
carcinoma. Mol Membr Biol. 2011;28:182–6.
11. Du X, Bao G, He X, Zhao H, Yu F, Qiao Q, Lu J, Ma Q. Expression and
biological significance of c-FLIP in human hepatocellular carcinomas. J Exp
Clin Cancer Res. 2009;28:24.
12. Ozturk S, Schleich K, Lavrik IN. Cellular FLICE-like inhibitory proteins (c-FLIPs):
fine-tuners of life and death decisions. Exp Cell Res. 2012;318:1324–31.
13. Shirley S, Micheau O. Targeting c-FLIP in cancer. Cancer Lett. 2013;332:141–50.
14. Hu WH, Johnson H, Shu HB. Activation of NF-kappaB by FADD, Casper, and
caspase-8. J Biol Chem. 2000;275:10838–44.
15. Kataoka T, Budd RC, Holler N, Thome M, Martinon F, Irmler M, Burns K,
Hahne M, Kennedy N, Kovacsovics M, et al. The caspase-8 inhibitor FLIP
promotes activation of NF-kappaB and Erk signaling pathways. Curr Biol.
2000;10:640–8.
16. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer
JL, Schroter M, Burns K, Mattmann C, et al. Inhibition of death receptor
signals by cellular FLIP. Nature. 1997;388:190–5.
17. Lee JS, Li Q, Lee JY, Lee SH, Jeong JH, Lee HR, Chang H, Zhou FC, Gao SJ,
Liang C, et al. FLIP-mediated autophagy regulation in cell death control. Nat
Cell Biol. 2009;11:1355–62.
18. Wu YH, Kuo WC, Wu YJ, Yang KT, Chen ST, Jiang ST, Gordy C, He YW, Lai
MZ. Participation of c-FLIP in NLRP3 and AIM2 inflammasome activation.
Cell Death Differ. 2014;21:451–61.
19. Ishioka T, Katayama R, Kikuchi R, Nishimoto M, Takada S, Takada R,
Matsuzawa S, Reed JC, Tsuruo T, Naito M. Impairment of the ubiquitin-
proteasome system by cellular FLIP. Genes Cells. 2007;12:735–44.
20. Marini ES, Giampietri C, Petrungaro S, Conti S, Filippini A, Scorrano L, Ziparo
E. The endogenous caspase-8 inhibitor c-FLIPL regulates ER morphology
and crosstalk with mitochondria. Cell Death Differ. 2015;22:1131–43.
21. Zhang Y, Huang F, Wang J, Luo H, Wang Z. 2-DG-Regulated RIP and c-FLIP
Effect on Liver Cancer Cell Apoptosis Induced by TRAIL. Med Sci Monit.
2015;21:3442–8.
22. Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer
therapeutics. Cell Death Dis. 2013;4, e532.
23. Ferreira LM. Cancer metabolism: the Warburg effect today. Exp Mol Pathol.
2010;89:372–80.
24. Adekola K, Rosen ST, Shanmugam M. Glucose transporters in cancer
metabolism. Curr Opin Oncol. 2012;24:650–4.
25. Massari F, Ciccarese C, Santoni M, Brunelli M, Piva F, Modena A, Bimbatti D,
Fantinel E, Santini D, Cheng L, et al. Metabolic alterations in renal cell
carcinoma. Cancer Treat Rev. 2015.
26. Shuch B, Linehan WM, Srinivasan R. Aerobic glycolysis: a novel target in
kidney cancer. Expert Rev Anticancer Ther. 2013;13:711–9.
27. Parikh U, Marcus C, Sarangi R, Taghipour M, Subramaniam RM. FDG PET/CT
in pancreatic and hepatobiliary carcinomas: value to patient management
and patient outcomes. PET Clin. 2015;10:327–43.
28. Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer
treatment. Oncogene. 2006;25:4633–46.
29. Paplomata E, O'Regan R. The PI3K/AKT/mTOR pathway in breast cancer:
targets, trials and biomarkers. Ther Adv Med Oncol. 2014;6:154–66.
30. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H,
Cinalli RM, Alavi A, Rudin CM, et al. Akt stimulates aerobic glycolysis in
cancer cells. Cancer Res. 2004;64:3892–9.
31. Semenza GL. HIF-1: upstream and downstream of cancer metabolism.
Curr Opin Genet Dev. 2010;20:51–6.
32. Quintavalle C, Incoronato M, Puca L, Acunzo M, Zanca C, Romano G,
Garofalo M, Iaboni M, Croce CM, Condorelli G. c-FLIPL enhances anti-
apoptotic Akt functions by modulation of Gsk3beta activity. Cell Death
Differ. 2010;17:1908–16.
33. Hirayama A, Kami K, Sugimoto M, Sugawara M, Toki N, Onozuka H, Kinoshita
T, Saito N, Ochiai A, Tomita M, et al. Quantitative metabolome profiling of
colon and stomach cancer microenvironment by capillary electrophoresis
time-of-flight mass spectrometry. Cancer Res. 2009;69:4918–25.
34. Lu J, Tan M, Cai Q. The Warburg effect in tumor progression: mitochondrial
oxidative metabolism as an anti-metastasis mechanism. Cancer Lett. 2015;
356:156–64.
35. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose
transporters. Physiol Rev. 2011;91:733–94.
36. Weihua Z, Tsan R, Huang WC, Wu Q, Chiu CH, Fidler IJ, Hung MC. Survival of
cancer cells is maintained by EGFR independent of its kinase activity. Cancer
Cell. 2008;13:385–93.
37. He MX, He YW. A role for c-FLIP(L) in the regulation of apoptosis, autophagy,
and necroptosis in T lymphocytes. Cell Death Differ. 2013;20:188–97.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Lei et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:79 Page 11 of 11
